FDA Approves Medtronic’s VenaSeal To Treat Venous Reflux
This article was originally published in The Gray Sheet
Executive Summary
VenaSeal was developed by Sapheon Inc., which Covidien acquired in the summer of 2014 shortly after it announced plans to merge with Medtronic.
You may also be interested in...
New Product Briefs
Product news from Revision Optics, Medtronic, Pryor Medical, Interventional Spine and Merit Medical.
Medtronic’s VenaSeal Closure System Receives FDA Approval For Treating Chronic Venous Disease
Adding to its product portfolio for treating superficial venous reflux, Medtronic has now received US approval for a more minimally invasive device, the VenaSeal closure system, which uses adhesive injections to seal the diseased vein in select patients with chronic venous insufficiency. Superficial venous reflux can lead to symptomatic varicose veins.
Covidien Further Bulks Up Vascular Biz With Sapheon Buy
Just one week after inking a deal to buy neurovascular product firm Reverse Medical, Covidien announced the purchase of another vascular device maker, Sapheon, which focuses on venous disease treatments.